Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Debunking Myths in the US Healthcare System
Top Ten Searches
gynecomastia empyema henoch–schönlein otitis media dyspnea jaundice ventricle lyme immunodeficiency coolingYour Article Summary
See Latest ArticlesThe ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease
International Journal of Geriatric Psychiatry, 06/30/09
A 4-point ADAS-cog change at 6 months is clinically meaningful for groups. Substantial individual misclassification between the ADAS-cog and clinical measures suggests no inherent meaning to a 4-point ADAS-cog change for a given patient.
Methods- Secondary analysis of the video imaging synthesis of treating Alzheimer's disease (VISTA) study: a 4-month, multi-centre, parallel-group, double-blind, placebo-controlled, trial of galantamine in 130 mild-moderate Alzheimer's disease patients (4-month open-label follow-up).
- ADAS-cog responses at 6 months were compared with outcomes on three clinical measures: clinician's interview based impression of change-plus caregiver input (CIBIC+), patient/carer-goal attainment scaling (PGAS) and clinician-GAS (CGAS).
- Thirty-seven of 99 patients improved by 4 points on the ADAS-cog at 6 months, and 16/99 showed 4-point worsening.
- ADAS-cog change scores correlated notionally to modestly with changes on the CGAS (r = -0.31), the PGAS (r = -0.29) and the CIBIC+ (r = 0.31).
- As a group, patients with ADAS-cog improvement were significantly more likely to improve on the clinical measures; those who worsened showed non-significant clinical decline.
- Individually, about half were misclassified in relation to each clinical measure; often when the ADAS-Cog detected no change, clinically meaningful effects could be detected. Even so, no ADAS-Cog cut-point optimally classified patients' clinical responses.
Today in Child/Adolescent Psych...keeping you current
Receive free subspecialty "5-minute updates" via email
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/28/09
How adolescents who cut themselves differ from those who take overdoses
European Child and Adolescent Psychiatry, 10/05/09
A Double-Blind, Randomized, Placebo-Controlled Study of Fixed-Dose Aripiprazole in Children and Adolescents With Autistic Disorder
Journal of the American Academy of Child and Adolescent Psychiatry, 10/06/09
Sponsor
Article Search
Sponsor
Sponsor